>>18457285 (lb)
of course.
your state and county health executives, the Federal Government,, and their counterparts within the EU and further abroad all signed or received these contracts for their covid vaccines.
EU Parliament MEP from Romania Cristian Terhes
Romanien MEP Cristian Terhes, question for Moderna and Pfizer: "These vaccines were ready in 2017!"
Transparency
> 2017
Removing the Viral Threat: Two Months to Stop Pandemic X from Taking Hold
DARPA aims to develop an integrated end-to-end platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less
OUTREACH@DARPA.MIL
2/6/2017
Over the past several years, DARPA-funded researchers have pioneered RNA vaccine technology, a medical countermeasure against infectious diseases that uses coded genetic constructs to stimulate production of viral proteins in the body, which in turn can trigger a protective antibody response. As a follow-on effort, DARPA funded research into genetic constructs that can directly stimulate production of antibodies in the body.1,2 DARPA is now launching the Pandemic Prevention Platform (P3) program, aimed at developing that foundational work into an entire system capable of halting the spread of any viral disease outbreak before it can escalate to pandemic status. Such a capability would offer a stark contrast to the state of the art for developing and deploying traditional vaccines—a process that does not deliver treatments to patients until months, years, or even decades after a viral threat emerges.
“DARPA’s goal is to create a technology platform that can place a protective treatment into health providers’ hands within 60 days of a pathogen being identified, and have that treatment induce protection in patients within three days of administration. We need to be able to move at this speed considering how quickly outbreaks can get out of control,” said Matt Hepburn, the P3 Program Manager. “The technology needs to work on any viral disease, whether it’s one humans have faced before or not.”
Recent outbreaks of viral infectious diseases such as Zika, H1N1 influenza, and Ebola have cast into sharp relief the inability of the global health system to rapidly contain the spread of a disease using existing tools and procedures. State-of-the-art medical countermeasures typically take many months or even years to develop, produce, distribute, and administer. These solutions often arrive too late—if at all—and in quantities too small to respond to emerging threats. In contrast, the envisioned P3 platform would cut response time to weeks and stay within the window of relevance for containing an outbreak.
Key to this undertaking are nucleic-acid-based technologies—those that are centered on DNA and RNA—including some developed under DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program. Using these tools, scientists can identify protective antibodies from recovering patients and then, through a biological version of reverse engineering, manufacture genetic constructs that, when delivered, can instruct an individual’s body to produce similar protective antibodies. Significant quantities of these nucleic acid “blueprints” can be rapidly manufactured compared to state-of-the-art antibody production methods.
p1
What is required now are breakthroughs in three other technology areas to bridge those past DARPA achievements and overcome the remaining bottlenecks that hinder rapid response to pandemic threats. The P3 program will pursue innovations in those three areas:
Growing virus needed to support evaluation of therapies in laboratory tests;
Subjecting antibodies to rapid rounds of evolution outside of the body to increase their potency beyond that of even the most effective antibodies obtained from infected patients; and
Developing means of efficiently delivering nucleic-acid-based protective treatments, since the technologies used to administer conventional vaccines do not readily translate.
Achieving and integrating breakthroughs in all of these areas will require choreographed cooperation among researchers and engineers specializing in such areas as immunology, microbiology, virology, medical infectious diseases, molecular biology, and medical countermeasure product development and manufacturing.
DARPA-funded teams will be required to demonstrate their integrated platforms in five simulations during the planned four-year program; they will initially test their platforms using pathogens of their choice, but ultimately they will test using DARPA-selected pathogens, including two demonstrations in which the identity of the pathogen will remain opaque to the teams until the 60-day clock starts. To ensure the developed platforms can produce a quality product with a viable pathway for regulatory review, each team will be required to complete a Phase I clinical safety trial before the end of the program.
A benefit of the nucleic-acid-based approach to limiting the spread of infection is that the genetic constructs introduced to the body would be processed quickly and would not integrate into an individual’s genome. Similarly, the antibodies produced in response to the treatment would only be present in the body for weeks to months. This is consistent with DARPA's intent with P3, which is to safely deliver transient immunity to a virus, halting the spread of disease by creating a firewall.
“Our country asks our military Service members to deploy globally and provide humanitarian assistance in all manner of high-risk environments. We owe it to them to develop the best protections possible,” said Hepburn, a U.S. Army physician who previously served as Director of Medical Preparedness on the White House National Security Staff. “If we’re successful, DARPA could take viral infectious disease outbreaks off the table as a threat to U.S. troops and as a driver of global instability.”
To further clarify the P3 program vision, answer questions from potential proposers, and facilitate teaming, DARPA is hosting two identical Proposers Days. The first will be at the Crown Plaza Tysons Corner McLean Hotel in McLean, Va., on February 22, 2017, and the second at the Doubletree by Hilton Hotel San Diego Downtown in San Diego on March 2, 2017. For registration information, visit: http://www.cvent.com/d/9vqy52.
Full details of the P3 program are included in a Broad Agency Announcement, available at: http://go.usa.gov/x9FbG. Proposal abstracts are due by 12:00 PM ET on March 13, 2017. Full proposals are due by 5:00 PM ET on May 1, 2017.
# # #
Image caption: The Pandemic Prevention Platform (P3) program aims to develop an integrated platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less. Using nucleic-acid-based technologies pioneered by DARPA as a foundation, the program now seeks to create an end-to-end platform by developing technologies to overcome remaining bottlenecks that hinder rapid response to pandemic threats. The three required technology areas cover growth of virus to support testing of treatments; rapid evolution of protective antibodies outside of the body; and safe and efficient delivery of nucleic-acid-based protective treatments.
Media with inquiries should contact DARPA Public Affairs at outreach@darpa.mil
2 of 2
https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html
DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics™
Research to focus on antibody production for immune defense
NEWS PROVIDED BY
Moderna Therapeutics
Oct 02,2013, 08:00 ET
CAMBRIDGE, Mass., Oct. 2, 2013 /PRNewswire/ – Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.
Messenger RNA therapeutics™ can be designed to tap directly into the body's natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, Moderna's messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.
"We are honored to be chosen by DARPA for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases," said Stephane Bancel, president and founding CEO of Moderna. "We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team's progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area."
This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million "seedling" grant from DARPA in March to begin work on the project.
This grant is part of a DARPA program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.
About DARPA
The Defense Advanced Research Projects Agency (DARPA) is the primary innovation engine of the Department of Defense. DARPA is responsible for the development of new technologies for use by the military. To deliver on its mission, DARPA challenges the status quo and thinks outside of, and well beyond, prevailing perspectives. The Agency relies on diverse performers to apply multi-disciplinary approaches to advance knowledge through basic research and to create innovative technologies that address current practical problems through applied research. DARPA is a project based agency that sets challenging objectives with their grantees to achieve revolutionary capabilities. The agency's leadership regularly weighs the progress of each program in the context of their overall portfolio to make judgment calls to either redirect funding or to accelerate specific efforts.
About Moderna Therapeutics
Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including 144 patent applications with 6,910 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.
For information contact:
Dan Quinn
Feinstein Kean Healthcare
617-761-6732
dan.quinn@fkhealth.com
SOURCE Moderna Therapeutics
https://news.clearancejobs.com/2013/12/04/pfizer-awarded-darpa-biodefense-contract-dod-daily-contracts/
Pfizer Awarded DARPA Biodefense Contract– DoD Daily Contracts
Lindy Kyzer / Dec 4,2013
DEFENSE ADVANCED RESEARCH PROJECTS AGENCY
Pfizer, Inc., has been awarded a $7,670,632 technology investment agreement. Pfizer shall perform a research and development program designed to develop a technology platform to identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual. Work will be performed in Cambridge, Mass. The estimated completion date is Dec. 8, 2016. Fiscal 2013 research and development funds are being obligated at time of award. The contracting activity is the Defense Advanced Research Projects Agency, Arlington, Va., (HR0011-14-3-0001).
Not James, and Never.
The US Government, the entire UN member roster, and their FED/BIS owners all contracted pfizer et al to deliver a product for them with specific requirements, on a time line, and for a specific budget.
Either these pharmakeia companies failed to deliver, or they did exactly what was ordered by your and every other complicit government.
Not to mention their knowledge of and involvement in the technology known as SarCov2…
ALL. OF. THEM.
warp speed delivered the DOD/DARPA contracted technology to the world. every president since at least 2013 has been aware of the 'program'/ Vote harder though.
You clearly did not look at my posts on this bred before responding with this. kek!
"I" did not publish those reports in 2013 and 2017, Miss.
B52s & Tankers now Circling over N Poland
https://twitter.com/wipljw/status/1632745456793968644
360°Radar
@wipljw
Refueling
🇺🇸2 x Boeing B-52H Stratofortress
🇺🇸2 x Boeing KC-135R Stratotanker
15:10
Israeli airstrikes on Aleppo/Syria
https://twitter.com/sentdefender/status/1632887353332072452
OSINTdefender
@sentdefender
Fires can be seen burning at Aleppo International Airport in Northwestern Syria after reported Israeli Airstrikes on Iranian-Backed Positions at the Airport.
Quote Tweet
Aleph א
@no_itsmyturn
·
2h
Aleppo airport was targeted by alleged #IAF 🇮🇱.
Nayrab reportedly hosts #IRGC-affiliated forces.
Show this thread
https://twitter.com/no_itsmyturn/status/1632885307514269698
Bernie's Tweets
@BernieSpofforth
EDUCATION - To save the world “farming needs to stop”
Our youth & future brainwashed by corporations & unelected bodies nudging & pushing them into a life of servitude to governments that can’t feed or clothe them, without farming.
End. Of. Days 🔥
https://twitter.com/BernieSpofforth/status/1632439865840226304
>Nothing Can Stop What Is Coming!
Who mentioned the ongoing degradation of the magnetosphere as part of the cycle that includes the upcoming micronova and pole shft at CPAC? Didn't see it in any notables…
72 hours or so after grid failure
until they are in all of the positions that manage the farm when you are the old livestock.
Solar Micronova | The End of an Age
No one has or will. That was anons point.
Yet many trust them (medea and politricksters) and keep voting and supporting and 'hoping' while they deceive, prepare, and attempt to keep all in the dark- jabbing them and starving them to death. (Not necessarily you, anon, but those still spellbound by the acting and actions of elections, media, and government.)
https://twitter.com/melaniatrump/status/584471762026401792
So many 'anons' are willfully BLIND.
There is only one path to the Father. And it aint witchcraft, necromancy, spirit summoning, nor any other magic